Cryoport inc (NASDAQ: CYRX) |
|
Price: $6.8100
$-0.20
-2.853%
|
Day's High:
| $7.025
| Week Perf:
| -7.72 %
|
Day's Low: |
$ 6.63 |
30 Day Perf: |
-20.35 % |
Volume (M): |
206 |
52 Wk High: |
$ 20.11 |
Volume (M$): |
$ 1,405 |
52 Wk Avg: |
$10.38 |
Open: |
$6.96 |
52 Wk Low: |
$5.32 |
|
|
Market Capitalization (Millions $) |
337 |
Shares
Outstanding (Millions) |
49 |
Employees |
31 |
Revenues (TTM) (Millions $) |
226 |
Net Income (TTM) (Millions $) |
-166 |
Cash Flow (TTM) (Millions $) |
-15 |
Capital Exp. (TTM) (Millions $) |
28 |
Cryoport Inc
We provide cryogenic logistics solutions to the life sciences industry through
a combination of proprietary packaging, information technology and specialized
cold chain logistics knowhow. We view our solutions as disruptive to the “older
technologies” of dry ice and liquid nitrogen, in that our solutions are
comprehensive and combine our competencies in configurations that are customized
to our client’s requirements. We provide comprehensive, reliable, economic
alternatives to all existing logistics solutions and services utilized for frozen
shipping in the life sciences industry (e.g., personalized medicine, cell therapies,
stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos,
cord blood, bio-pharmaceuticals, infectious substances, and other commodities
that require continuous exposure to cryogenic or frozen temperatures). As part
of our services we provide the ability to monitor, record and archive crucial
information for each shipment that can be used for scientific and regulatory
purposes.
Our Cryoport Express® Solutions include a sophisticated cloud-based logistics
operating platform, which is branded as the Cryoportal™. The Cryoportal™
supports the management of the entire shipment and logistics process through
a single interface, including initial order input, document preparation, customs
clearance, courier management, shipment tracking, issue resolution, and delivery.
In addition, it provides unique and incisive information dashboards and validation
documentation for every shipment. The Cryoportal™ records and retains
a fully documented “chain-of-custody” and, at the client’s
option, “chain-of-condition” for every shipment, helping ensure
that quality, safety, efficacy, and stability of shipped commodities are maintained
throughout the process. This recorded and archived information allows our clients
to meet exacting requirements necessary for scientific work and for proof of
regulatory compliance during the logistics phase.
The branded packaging for our Cryoport Express® Solutions includes our liquid
nitrogen dry vapor shippers, the Cryoport Express® Shippers. The Cryoport
Express® Shippers are cost-effective and reusable cryogenic transport containers
(our standard shipper is a patented vacuum flask) utilizing an innovative application
of “dry vapor” liquid nitrogen (“LN2”) technology. Cryoport
Express® Shippers are International Air Transport Association (“IATA”)
certified and validated to maintain stable temperatures of minus 150° C
and below for a 10-day dynamic shipment period. The Company currently features
three Cryoport Express® Shippers: the Standard Dry Shipper (holding up to
75 2.0 ml vials), the High Volume Dry Shipper (holding up to 500 2.0 ml vials)
and the recently introduced Cryoport Express® CXVC1 Shipper (holding up
to 1,500 2.0 ml vials). In addition, we assist clients with internal secondary
packaging (e.g., vials, canes, straws and plates).
Our most used solution is the “turnkey” solution, which can be accessed
directly through our cloud-based Cryoportal™ or by contacting Cryoport
Client Care for order entry. Once an order is placed and cleared, we ship a
fully charged Cryoport Express® Shipper to the client who conveniently loads
its frozen commodity into the inner chamber of the Cryoport Express® Shipper.
The customer then closes the shipper package and reseals the shipping box displaying
the next recipient’s address (“Flap A”) for pre-arranged carrier
pick up. Cryoport arranges for the pick-up of the parcel by a shipping service
provider, which is designated by the client or chosen by Cryoport, for delivery
to the client’s intended recipient. The recipient simply opens the shipper
package and removes the frozen commodity that has been shipped. The recipient
then reseals the package, displaying the nearest Cryoport Staging Center address,
making it ready for pre-arranged carrier pick-up. When the Cryoport Staging
Center receives the Cryoport Express® Shipper, it is cleaned, put through
quality assurance testing, and returned to inventory for reuse.
“Customer Staged Solution,” designed for clients making 50 or more
shipments per month. Under this solution, we supply an inventory of our Cryoport
Express® Shippers to our customer, in an uncharged state, enabling our customer
(after training/certification) to charge them with liquid nitrogen and use our
Cryoportal™ to enter orders with shipping and delivery service providers
for the transportation of the package.
“Customer Managed Solution,” a limited customer implemented solution,
whereby we supply our Cryoport Express® Shippers to clients in a fully charged
state, but leaving it to the client to manage the shipping, including the selection
of the shipping and delivery service provider and the return of the shipper
to us.
“powered by CryoportSM,” available to providers of shipping and
delivery services who seek to offer a “branded” cryogenic logistics
solution as part of their service offerings, with “powered by CryoportSM”
appearing prominently on the offering software interface and packaging. This
solution can also be private labeled upon meeting certain requirements, such
as minimum required shipping volumes.
“Integrated Solution,” which is our total outsource solution. It
is our most comprehensive solution and involves our management of the entire
cryogenic logistics process for our client, including Cryoport employees at
the client’s site to manage the client’s cryogenic logistics function
in total.
“Regenerative Medicine Point-of-Care Repository Solution,” designed
for allogeneic therapies. In this solution we supply our Cryoport Express®
Shipper to ship and store cryogenically preserved life science products for
up to six days (or longer periods with supplementary shippers) at a point-of-care
site, with the Cryoport Express® Shipper serving as a temporary freezer/repository
enabling the efficient and effective distribution of temperature sensitive allogeneic
cell-based therapies without the expense, inconvenience, and potential costly
failure of an on-sight, cryopreservation device.
“Personalized Medicine and Cell-based Immunotherapy Solution,” designed
for autologous therapies. In this solution our Cryoport Express® Shipper
serves as an enabling technology for the safe transportation of manufactured
autologous cellular-based immunotherapy market by providing a comprehensive
logistics solution for the verified chain of custody and condition transport
from, (a) the collection of the patient’s cells in a hospital setting,
to (b) a central processing facility where they are manufactured into a personalized
medicine, to (c) the safe, cryogenically preserved return of these irreplaceable
cells to a point-of-care treatment facility. If required, the Cryoport Express®
Shipper can then serve as a temporary freezer/repository to allow the efficient
distribution of this personalized medicine to the patient when and where the
medical provider needs it most without the expense, inconvenience, and potential
costly failure of an on-sight, cryopreservation device.
Company Address: 112 Westwood Place, Suite 350 Brentwood 37027 TN
Company Phone Number: 470-2300 Stock Exchange / Ticker: NASDAQ CYRX
|
|
Customers Net Income fell by |
CYRX's Customers Net Profit Margin fell to |
-49.98 % |
15.95 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Stocks on the Move
Published Fri, Jul 12 2024 11:30 AM UTC
CryoPort Inc: Turbulent Times and Investigative Claims Shake Shares, but Collaborative Partnerships Provide HopeCryoPort, Inc. (NASDAQ: CYRX) has witnessed a rollercoaster ride in its stock performance, facing significant sell-offs followed by a brief surge in share prices. Investors have raised concerns surrounding the company s financial health, as well as ongoing investig...
|
Cryoport Inc
As a financial analyst covering Cryoport Inc for the CSIMarket.com, I have been closely monitoring the company's recent financial results for the first quarter of 2024. The numbers paint a mixed picture for the innovative provider of cold chain logistics solutions in the life sciences industry. One key takeaway from the financial report is the widening deficit per share, which stood at $-0.43 for the first quarter of 2024 compared to $-0.16 in the same period last year. However, there is a silver lining in the form of an improvement in earnings per share, which came in at $-1.30 per share for the quarter, an improvement from the prior reporting season.
|
Cryoport Inc
Cryoport Inc, a major player in the pharmaceutical preparations industry, recently released its financial results for the fourth quarter of the 2023 earnings season. The company reported a significant increase in its deficit per share, with a deficit of $-1.30 per share compared to $-0.22 in the same period the previous year. This represents a huge surge in deficit from the previous reporting period, where it was $-0.31 per share. In terms of revenue, Cryoport Inc experienced a decrease of -5.133%, with revenue totaling $57.26 million compared to $60.36 million in the corresponding reporting period a year before. However, there was a slight sequential increase of 1.964% from the previous quarter.
|
Cryoport Inc
Cryoport Inc, a leading provider of cold chain logistics solutions, has seen its stock gain 16.5% over the last five trading days, demonstrating some positive momentum. However, while this may seem promising, it is important to examine the recent financial results to understand the potential implications for the company's future. 1. Declining Revenue and Widening Losses: In the most recent fiscal period, Cryoport Inc experienced a decline in revenue to $56.16 million, a decrease of 7.123% compared to the previous year. This decrease can be attributed to lower demand, which has resulted in fading revenue. Furthermore, the company's net loss for the period amounted to $-15.269 million, surpassing the $-7.316 million loss recorded in the previous year. The persisting losses pose significant challenges to Cryoport Inc's profitability and long-term sustainability.
|
Cryoport Inc
Date: [Today's Date] Cryoport Inc, a leading provider of critical temperature logistics solutions for the life sciences industry, has reported disappointing financial results for the second quarter of 2023. The company's loss per share increased to $-0.42 compared to $-0.23 a year ago, representing a significant surge from the previous financial reporting period's loss of $-0.16 per share. Revenue for the April to June 30, 2023 span declined considerably by -11.117% to $57.02 million from $64.15 million in the corresponding financial reporting period a year ago. Sequentially, revenue deteriorated by -9.227% from $62.82 million. This decline is in stark contrast to the on-average Major Pharmaceutical Preparations sector, which recorded a 2.65% growth in revenue relative to Q2 2022 in the second quarter of 2023.
|
Per Share |
Current |
Earnings (TTM) |
-3.37 $ |
Revenues (TTM) |
4.58 $
|
Cash Flow (TTM) |
- |
Cash |
5.55 $
|
Book Value |
8.47 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-3.37 $
|
Revenues (TTM) |
4.58 $ |
Cash Flow (TTM) |
- |
Cash |
5.55 $
|
Book Value |
8.47 $ |
Dividend (TTM) |
0 $ |
|
|
|
|